The "RNAi Therapeutics and Technologies Market" report features an extensive study of the current market landscape and the likely future potential; associated with the RNAi therapeutics market, over the next decade

Key Inclusions
1. A detailed overview of the overall market landscape of players engaged in the development of RNAi therapeutics, based on several relevant parameters, such as phase of development (marketed, clinical, and preclinical / discovery stage) of pipeline candidates, target disease indication(s), key therapeutic areas (oncological disorders, infectious diseases, genetic disorders, ophthalmic diseases, respiratory disorders, hepatic disorders, metabolic disorders, cardiovascular disorders, dermatological disorders and other disorders), type of RNAi molecule (siRNA, miRNA, shRNA, sshRNA and DNA), target gene, route of administration and special drug designations (if any).
2. A detailed overview of the players engaged in the development of RNAi therapeutics, based on several relevant parameters, such as year of establishment, company size, location of headquarters and regional landscape.
3. A competitiveness analysis of RNAi therapeutic developers, based on developer strength (in terms of employee count and years of experience) and product portfolio strength (in terms of number of RNAi molecules across different phases of development, type of RNAi molecule offered, purpose of technology and target therapeutic area).

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/rnai-therapeutics-market-2nd-edition-2019-2030/request-quote.html

4. Elaborate profiles of drug candidates that are in the advanced stages of development (phase II / III and above). Each drug profile features information on the current development status of the drug, along with details on its developer, mechanism of action, route of administration, affiliated technology Platform (if available), dosage and recent clinical trial results.
5. An overview of the current market landscape of technology platforms available for the development of RNAi therapeutics, along with information on their developer, purpose of technology, type of molecule (s) delivered and type of cell (s) / tissue (s) targeted. In addition, the chapter includes information on technology developer(s), highlighting the year of their establishment, company size and location of headquarters. The chapter also includes brief profiles of key RNAi-based drug discovery / development technology platforms and drug delivery technologies (shortlisted on the basis of competitiveness score). Each profile features details on the various pipeline molecules that have been / are being developed using the technology and insights from patents associated with the technology.
6. An insightful technology competitiveness analysis, benchmarking RNAi technologies, based on supplier power (in terms of company size and years of experience) and key technology specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.
7. A detailed analysis of the target indications (segregated by various therapeutic areas, including oncological disorders, infectious diseases, metabolic disorders, ophthalmic diseases and genetic disorders) that are currently the prime focus of companies engaged in the development of RNAi therapeutics.

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/rnai-therapeutics-market-2nd-edition-2019-2030/request-sample.html

8. An analysis of completed, ongoing and planned clinical studies, based on several relevant parameters, such as trial registration year, current status, phase of development, type of RNAi molecule, enrolled patient population and regional distribution of trials.
9. An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2X2 analysis to assess the relative experience of certain KOLs who were shortlisted based on their contributions (in terms of involvement in various clinical studies) in this field.
10. An in-depth analysis of patents related to RNAi therapeutics, filed / granted, since 2016, based on type of patent (granted patents, patent applications and others), publication year, regional applicability, CPC symbols, emerging focus areas, leading industry / non-industry players (in terms of the number of patents filed / granted), and patent valuation.
11. A detailed review of around 3,000 peer-reviewed, scientific articles related to research on RNAi therapeutics, based on several relevant parameters, such as year of publication, type of publication, popular keywords, top journals, top publishers, key copyright holders and key funding institutes.
12. An analysis of the various partnerships related to RNAi therapeutics inked by players engaged in this domain, based on various parameters, such as the type of partnership, year of partnership, target disease indication, therapeutic area, type of RNAi molecule, financial details (wherever applicable), focus area of collaboration and most active players (in terms of number of partnerships).
13. A detailed analysis of various investments made by players engaged in this domain, during the period 2016-2021, based on several relevant parameters, such as year of funding, type of funding (seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other offerings), amount invested, type of RNAi molecule, most active players (in terms of number and amount of funding instances) and key investors (in terms of number of instances).
14. An elaborate discussion on the various commercialization strategies that can be adopted by drug developers engaged in this domain, across different stages of therapy development, including prior to drug launch, at / during drug launch and post-marketing of the drug.
15. An elaborate discussion on the use of miRNA as a potential biomarker, along with a list of diagnostic kits that are either available in the market, or likely to be approved in the foreseen future.
16. A detailed analysis of the companies that are actively supporting the development of RNAi therapeutics market, including contract manufacturers, contract researcher organizations and other service providers based on various parameters, such as type of service provider, location of their headquarters and type of RNAi molecule developed.
17. An informed estimate of the annual clinical and commercial demand for RNAi therapeutics, taking into account the target patient population in ongoing and planned clinical trials of RNAi therapeutics, sponsored by both industry and non-industry players.
18. A detailed analysis capturing affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the RNAi therapeutics market.
19. Informed estimates on the evolution of the market for the period 2022-2035. The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

Key Therapeutic Areas
1. Oncological Disorders
2. Genetic Disorders
3. Metabolic Disorders
4. Hematological Disorders
5. Ophthalmic Disorders
6. Others

Routes of Administration
1. Subcutaneous
2. Intravenous
3. Topical
4. Intradermal

Types of RNAi Molecules
1. siRNA
2. shRNA

Key Geographical Regions
1. North America
2. Europe
3. Asia-Pacific and the Rest of the World

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/rnai-therapeutics-market/278.html

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.